Elena is recognized expert and leader of the Russian pharmaceutical industry, has 25 years of experience in leading international pharmaceutical companies, one of 25 women CEO of Russia according to RBC.
2019 till present – President of the company Takeda Pharmaceuticals Russia
2014-2019 General Manager, Abbott Russia
2011-2014 General Manager, Meda Pharmaceuticals
1995-2011 kept different positions in sales and marketing in such pharmaceutical companies as Pliva (Croatia), Novartis Pharma (Switzerland), Sanofi (France).
1990-1993 graduated from the Oncology Institute of Russian Academy of Sciences., PhD.
1987 graduated from the Moscow Medical Academy n.a. Sechenov, Department of General Medicine.
Katerina began her career with Janssen in 2001, holding a number of positions in the Sales, Marketing and Market Access teams. She has been a member of the Russian board of directors since 2010 and was appointed Country Manager Russia in 2015, and then she was promoted to the position of Managing Director Russia & CIS in 2017. In April 2019 Katerina was appointed CEO of Johnson & Johnson Russia & CIS.
Throughout her 17-year career with Janssen, Katerina has consistently demonstrated high standards of quality and strong results. She led the launch of a whole range of new products and work across a number of therapeutic areas, as well as establishing several new business units. In her role as Commercial Operations Director, Russia, Katerina successfully led commercial teams in close collaboration with other departments, which yielded great business results and drove the company’s overall success.
Katerina graduated with distinction from the International University in Moscow, where she studied law. She also completed specialist education for senior executives at the London School of Economics and Political Science and Moscow School of Management Skolkovo.
Dr. Stephan Eder is Executive Vice President of STADA in the Russia and CIS region, and a member of the Global STADA Executive Committee. In this role, he oversees all operations in STADA Russia as well as in the CIS countries. Russia is with more than 3000 employees the second largest business within the global STADA Group.
He joined STADA from Sandoz, where he most recently served as CEO Hexal and Country Head Sandoz Germany from mid-2017 onwards. With a clear vision, he led the German Sandoz team and business through a strategic transformation to drive increased customer focus, resulting in strong sales and profit growth as well as an expansion of market leadership in Germany.
Having started his career at McKinsey, Austrian national Stephan Eder was co-founder and CFO of the startup medicine-discovery company 55pharma before joining Sandoz’ parent group, Novartis, in 2007. After working in corporate strategy roles at Novartis, he subsequently led Sandoz’ portfolio management, business development and licensing function in Central and Eastern Europe before he was responsible for the Russian OTC operation from mid-2010 until end 2013. During this period under his leadership, the business almost doubled in size and strongly outgrew the Russian OTC market. Subsequently until mid-2017, Stephan Eder headed Sandoz’ operations in the UK and Ireland as General Manager, successfully growing the business and driving sustainable results in a highly volatile market.
General Manager Sanofi Eurasia from October 1, 2018. Prior to that since January 1, 2016 worked as General Manager, Rx, Sanofi Russia & Belarus.
Engineer by training with MBA degree from Cranfield School of Management, UK, Oxana has got more than nineteen years of in-depth knowledge and experience in pharmaceutical industry with a number of leadership roles in Marketing, Strategic Planning, and Sales in Russia and UK.
Oxana started her career in pharmaceutical industry in 2001 with Eli Lilly UK. Over the following 13 years, she took on a number of senior management positions with increasing responsibility. In 2014, Oxana joined Sanofi as a Head of Diabetes BU in Russia.
Adlane graduated in Marketing and Management from Lyon Business School and holds a Master’s Degree in International Trade from Lyon University.
Adlane Soudani joined Ipsen in France in 2005. He developed a specific expertise in the export business in several regions of the globe until he was promoted to Export Director for Latin America.
Building on his success in this role, in 2013 he was appointed General Manager, Ipsen in Algeria. In this position, he has been instrumental in building a strong team and leading it to reach record market shares for both the Specialty Care and Consumer Healthcare businesses.
Demonstrating a lot of resilience in a challenging market like Russia, Adlane successfully led the creation of a Joint-Venture in the country which has paved the way for building the first oncology factory in the Algeria.
In October 2018 Adlane was appointed a General Manager of Ipsen in Russia & CIS.
Since then the company has started its fantastic transformation journey. Within a relatively short period of time Adlane managed to develop new capabilities within the company to be more focused on innovation and breakthrough solutions in oncology and rare diseases. Thanks to the recently launched innovative breakthrough solution for kidney cancer treatment and other product yet to come for patients` unmet needs, Ipsen is transforming into one of the key players in oncology and orphan disease markets in Russia.
Adlane`s key focus in patient centricity and development of business in a compliant manner helped to bring innovation for the development of the company which can contribute to the development of the healthcare industry in Russia.
Elena owns more than 15 year experience in pharma with a proven track record in driving marketing, sales, and corporate strategy development.
Elena launched her professional career in Marketing in Boehringer Ingelheim, one of the leading German pharma companies, having worked there for 10 years. Moving forward, Elena had various executive positions in Russian, American and Indian pharma companies, gaining valuable international experience and building a wide network of contacts with partners.
Elena graduated from Baikal International Business School of Irkutsk State University (Siberian-American Department of Management). Also she has a degree of Global Executive MBA of Vienna University of Economics and Business and of University of Minnesota.
Since 2018, he has been the Executive Director of NANOLEK; in March 2020, he joined the Management Board of Nanolek LLC. During his work, he managed to increase the number of sales by several times, carried out global structural changes, bringing the company first profit and ensuring the export of medicines to the CIS countries.
Prior to joining NANOLEK, he had worked for companies such as Elly Lilly Vostok S.A., Pharmstandard, NPO PetrovaxPharm.
Maxim Stetsyuk graduated from the State Academy of Management, in2006–2008completed training in the University of Antwerp Management School (UAMS), has international certificates business schools.
«If we talk about developing a common strategy within the framework of healthcare, we must remember that a profitable investment is a contribution to disease prevention».
«Our company has a GMP quality certificate and passes audits of foreign partners at least 1–2 times a month, and such a check can be passed only in one case: if you do not have a single violation throughout the entire production chain. I invite everyone to make sure of this at the NANOLEK plant in the Kirov region».
Rustam Iksanov, Vice President, R&D, co-developer of more than 10 inventions in the field of pharmacy, which are protected by patents of the Russian Federation.
Rustam Iksanov has been working in the Russian pharmaceutical market for more than 20 years. Before joining NovaMedica he took the position of M&A Director in Valenta Pharm where he managed the business development of Gastroenterology division. He developed strategic scenarios of product portfolio development, managed pipeline projects and was responsible for search of potential targets for acquisition (products, developments and companies), preparation and implementation of deals.
Earlier Rustam was Vice President for Strategic Development in Akrikhin (Polpharma), he also hold managerial positions in the field of development products and product portfolio in Izvariono Pharma (Ferring Pharmaceuticals) and Nizhpharm (Stada). Before that, he held classes at the Nizhny Novgorod State Medical Academy and worked as a physician.
Rustam graduated with honors from the Nizhny Novgorod State Medical Academy. In addition, he undertook special programs devoted to commercialization of technologies in the Russian Presidential Academy of National Economy and to pharmaceutical management and economics in the Peoples’ Friendship University of Russia.
Vera graduated from The first Moscow Medical University named by I.M. Sechenov, clinical residency in the specialty "Anesthesiology and Reanimatology", and also received additional education at the Russian Medical Academy and the Institute of Additional Professional Education GASIS NRU HSE.
Vera has 5 years of experience in the healthcare as ICU Specialist, and 19 years of experience in the pharmaceutical industry in Russia and the CIS.
She began her career in the pharmaceutical business in the sales department as Medical Representative and then as District Manager for Pfizer's hospital and oncology business.
In 2006, Vera moved to the medical department and since then has been working and continuing her development in Medical Affairs, promoting from Medical Adviser to a Medical Director and gaining experience in 4 major international pharmaceutical companies in various therapeutic areas: oncology, onco-hematology, orphan diseases, ophthalmology, ICU, neurology, aesthetics, as well as in the vast field of infectious diseases.
In 2015 Vera was appointed Medical Director of Alexion Pharma, where she was responsible for Russia and the CIS. In this role, Vera managed to form a professional team of the medical department, with which she launched patient support and education programs, educational programs for doctors, increased the compliance of the company's medical processes, which was recognized by the global leadership as the best practice.
In 2019, she joined Ipsen as Medical Director for Russia and the CIS. Under Vera's leadership, Ipsen's medical function underwent a significant transformation, becoming one of the key drivers of the company's development.
+ 10 years of working experience in public
administration in customer Service, and
at Merck in the supply chain management
of medicinal products
Since February 2018: Supply Chain Head, Merck Biopharma Russia & CIS
2015 ~ 18 Demand Planning Manager; Merck Spain
2012 ~ 15 Customer Service Technician, Customer Service Manager; Open Administration Consortium
2006 ~ 12 Product Manager, Project Manager; Catalan Certification Agency
Mariya graduated from Medical University and Clinical Residency with a specialization in Cardiology and received the education in Strategic Management at business schools in Lausanne (Switzerland) and Singapore.
Mariya began her career in the pharmaceutical business as a medical representative, then gained experience in marketing and in 2009 became the head of the Nephrology Business Unit of Amgen. Having formed a strong sales & marketing team, Maria was able to bring the company's nephrology business to a qualitatively new level, demonstrating the highest results of work in the company for two years in a row.
In 2014, Maria accepted an offer to head a completely new direction for the company, standing at the origins of the formation of the Market Access function in the Russian pharmaceutical market and the CIS markets.
In 2018, in the role of Global Value Access & policy director for Russia and CEE countries, she moved to Alexion, where, under her leadership the company's leading drugs were included in the state drug lists. In 2019, Maria joined Ipsen as Market Access and Public Affairs Director, Russia & CIS, taking a course to strengthen the company's reputation as a reliable partner of the state and society, offering innovative solutions for patients in various therapeutic areas.
Ekaterina Creanga has an extensive experience in the field of pharmaceuticals and medical equipment. Ekaterina has carried out several successful projects of creation and transformation of business structures, formation of highly effective teams, and provision of stable business growth.
Prior to joining LifeScan, Ekaterina worked for Abbott where she held the position of General Director for Russia and the CIS of the cardiac implantable devices division. Also in Abbott, Ekaterina worked in the pharmaceutical division where she headed the OTC drugs department. Earlier, for 9 years, Ekaterina developed her career in the Novartis group of companies: initially in the generic division of Sandoz in the field of sales and marketing, and later she headed one of the subdivisions of the ophthalmological division of Alcon.
At the moment Ekaterina is introducing modern approaches with a focus on digital transformation in order to bring the LifeScan business in Russia to a new level.
Vladimir has been working at «36.6» since February 2018. In the beginning he held the position of Advisor to the Director General. In April 2018 he was assigned as CEO of PJSC Pharmacy Chain «36.6». Since October 2020 - member of the Board of Directors of «Pharmacy chain 36.6». Vladimir Nesterenko began his career in medicine as an anesthesiologist-resuscitator. Later he held senior positions in the Ministry of Health of the Russian Federation. He was the Deputy Head of Department for the Pharmaceutical Activity Agency, the provision of medicines and medical devices of the Ministry of Health of the Russian Federation; and he was the Deputy Minister of Health of the Moscow Region Government as well. Vladimir Nesterenko also was a member of the top management in the largest pharmaceutical companies, such as «PharmECO», «NOVAFARM», «BIOTEС». Ministry of Health of the Moscow Region awarded a commendation to Nesterenko V.M for conscientious work in 2002 and 2006.
Vice-President and Executive Director for Biomedical Technologies Cluster of Skolkovo Foundation. Natalia is responsible for developing innovative ecosystem and bringing innovative solutions to Healthcare, Pharmaceutical industry and Agro-tech.
Prior to joining Skolkovo in December, 2018 Natalia committed over twenty years to the pharmaceutical industry, holding top-managerial positions within leading pharmaceutical companies. Natalia started her career as a Medical Director at Bayer AG and later continued as a Regional Head for Ethical Products of Bayer HealthCare in Russia and CIS countries. In the following years Natalia held positions of Regional Business Head for Merck KGaA Oncology business in Russia and CIS countries, Chief Strategy Officer within the largest Russian pharmaceutical company Pharmstandard, General Manager in the Russian branch of the major world CRO Quintiles.
During that time Natalia has driven implementation of strategic innovations and best practices in all business functions across organization with special focus on pipeline development, precision medicine, multi-channel and patient-oriented solutions, while generating strong basis for companies’ substantial growth and leading position in the selected strategic markets. Elaborating her extensive experience, Natalia effectively led business transfer under several global M&As at country level, adopting cross-cultural approach for new company.
Natalia graduated from Moscow State Medical University and continued her professional education at Columbia University, School of Physicians & Surgeons, NYC, USA. Natalia holds scientific degree in NeuroScience and MBA degree from the American Institute of Business and Administration.